Status of treatment of vascular dementia

被引:15
作者
Lechner, H [1 ]
机构
[1] Inst Clin Neurophysiol & Neurorehabil, A-8010 Graz, Austria
关键词
vascular risk factors; platelet-aggregating inhibitors; hemorheologically active substances; heparin-induced plasmapheresis;
D O I
10.1159/000026148
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The therapeutic goal in treating vascular dementia has been based on its presumed association with cerebral arteriosclerosis. Therefore, it is necessary to control risk factors for arteriosclerosis. In this connection, application of platelet-aggregating substances has been used extensively, Promising results have also been observed by altering the hemorheologic profile because hemorheologically active substances may be able to ameliorate the course of vascular dementia. Further improvement could be achieved by application of the HELP system to enhance the effect of hemorheologically active drugs, Using the HELP system, LDL, cholesterol, triglycerides and fibrinogen can be lowered considerably and may result in clinical improvement or slowing of the progression of vascular dementia.
引用
收藏
页码:10 / 13
页数:4
相关论文
共 19 条
  • [1] *AM PSYCH ASS COMM, 1983, DIAGN STAT MAN MENT
  • [2] PENTOXIFYLLINE IN CEREBROVASCULAR DEMENTIA
    BLACK, RS
    BARCLAY, LL
    NOLAN, KA
    THALER, HT
    HARDIMAN, ST
    BLASS, JP
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1992, 40 (03) : 237 - 244
  • [3] DOMINGUEZ D, 1977, PHARMATHERAPEUTICA, V1, P498
  • [4] HACHINSKI VC, 1974, LANCET, V2, P207
  • [5] KONNO S, IN PRESS DRUGS AGING
  • [6] LECHNER H, 1996, J STROKE CEREBROVASC, V6, P184
  • [7] LECHNER H, 1988, VASCULAR MULTIINFARC, P101
  • [8] LECHNER H, 1990, PSYCHOGERIATRICS BIO, P288
  • [9] LECHNR H, 1992, WIEN KLIN WOCHENSCHR, V10, P290
  • [10] MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939